Besides, according to the (Effects of Empagliflozin on Cardiac Structure in Patients with Type 2 Diabetes) study, SGLT2 inhibition was associated with a significant reduction in left ventricular mass indexed to body surface area after 6 months in people with T2DM and CAD (12). The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.